Cover Image
市場調查報告書

胚胎著床前遺傳基因診斷市場分析:各類型 (染色體異常,組織相容抗原檢查,性聯隱性遺傳疾病,性別篩選,及遺傳基因疾病) 、各用途及市場區隔預測

Preimplantation Genetic Diagnosis Market Analysis By Type (Chromosomal Abnormalities, HLA typing, X-linked Diseases, Gender Selection, & Genetic Disorders), By Application, And Segment Forecasts To 2024

出版商 Grand View Research, Inc. 商品編碼 370435
出版日期 內容資訊 英文 76 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胚胎著床前遺傳基因診斷市場分析:各類型 (染色體異常,組織相容抗原檢查,性聯隱性遺傳疾病,性別篩選,及遺傳基因疾病) 、各用途及市場區隔預測 Preimplantation Genetic Diagnosis Market Analysis By Type (Chromosomal Abnormalities, HLA typing, X-linked Diseases, Gender Selection, & Genetic Disorders), By Application, And Segment Forecasts To 2024
出版日期: 2016年09月07日 內容資訊: 英文 76 Pages
簡介

本報告提供全球胚胎著床前遺傳基因診斷市場相關調查,彙整市場各類型,各用途,各地區別趨勢,今後預測,及加入此市場的主要企業簡介等資料。

第1章 調查方法與調查範圍

第2章 摘要整理

第3章 產業預測

  • 市場區隔
  • 市場規模與成長預測:2013∼2024年
  • 市場趨勢
    • 促進要素
    • 阻礙要素
  • 優先的主要機會
  • 產業分析:波特五力分析
  • PESTEL分析

第4章 診斷各類型預測

  • 各類型收益佔有率
  • 染色體異常
  • 組織相容抗原檢查
  • 性聯隱性遺傳疾病
  • 性別篩選
  • 其他遺傳基因疾病

第5章 各用途預測

  • 各用途收益佔有率
  • 幹細胞治療的HLA用胚胎鑑定
  • 體外受精患者的預後改善
  • 晚開性遺傳基因疾病
  • 遺傳性遺傳基因疾病
  • 其他的用途

第6章 各地區預測

  • 各地區收益佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第7章 競爭環境

  • F. Hoffmann-La Roche AG
  • Genea
  • Quest Diagnostics
  • Illumina Inc.
  • Natera
  • Genesis Genetics LLC
  • Reprogenetics LLC
  • Laboratory Corporation of America Holdings(LabCorp)
  • Reproductive Genetics Institute Inc.
  • California Pacific Medical Center

圖表

目錄
Product Code: GVR-1-68038-088-0

Global preimplantation genetic diagnosisis market expected to reach USD 96.8 million by 2024, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to the growing incidence of inherited single gene associated and late onset genetic disorders.

Ongoing introduction of advancements in in-vitro fertilization (IVF) methods are key factors that have a positive impact on the growth of this market. Incorporation of novel algorithms pertaining to genetic diagnosis using NGS technology are expected to fuel demand in the coming years.

Demand for successful embryo implantation in couples who are detected with certain chromosomal aberrations or fertility problems are also factors anticipated to boost growth in demand over the forecast period.

Further key findings from the study suggest:

Chromosomal abnormalities accounted for over 36% of the revenue generated in 2015. This large share can be attributed to growing usage of PGD techniques for detection of aneuploidies that are observed in higher aged maternal patients. Furthermore, presence of large product portfolio of different market players operating in chromosomal abnormality detection is responsible for large market share of this technique.

Embryo HLA typing for stem cell therapy accounted for over 32% of the revenue generated in the market for 2015. High incidence rate of single gene disorders and late onset hereditary oncology diseases that need to be treated in order to curb the mortality rate are major driver for growth of this segment.

Embryo implantation for treatment of the first child that is inherited with the chromosomal abnormality by the virtue of 'savior sibling' is attributive towards market growth. With expected development of this segment, the market will witness lucrative opportunities of growth over the forecast period.

North America dominated the market in 2015, with revenue estimated at over USD 35 million in 2015. Presence of sophisticated healthcare infrastructure, rising aneuploidy, and infertility rates, favorable government initiatives with respect to genetic diagnosis and its application in IVF are major factors driving growth of this region.

Asia Pacific is expected to witness lucrative growth from 2016 to 2024 due to the availability of cost-effective PGD procedures coupled with rapidly rising healthcare R&D investment, and growing medical expenditures in emerging economies of India and China.

Key participants of the preimplantation genetic diagnosis market include Genesis Genetics, LabCorp, Natera, Quest Diagnostics, Genea, Genzyme Corporation, Reproductive Genetics Institute, and F. Hoffman La Roche Ltd.

These participants are involved in R&D for development of tests that can detect several chromosomal abnormalities using single cell analysis and prevent inheritance of genetic imbalances.

Table of Contents

Chapter 1: Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2: Executive Summary

Chapter 3: Preimplantation Genetic Diagnosis Industry Outlook

  • 3.1. Market segmentation
  • 3.2. Market size and growth prospects, 2013-2024
  • 3.3. Preimplantation genetic diagnosis market dynamics
    • 3.3.1. Market driver analysis
      • 3.3.1.1. Rising incidences of genetic diseases
      • 3.3.1.2. Demand for healthy and successful embryo implantation
      • 3.3.1.3. Increase in rate of infertility
    • 3.3.2. Market restraint analysis
      • 3.3.2.1. Ethical and legal constraints
  • 3.4. Key opportunities prioritized, 2015
  • 3.5. Industry analysis-Porter's
  • 3.6. Preimplantation genetic diagnosis PESTEL Analysis

Chapter 4: Preimplantation Genetic Diagnosis Type Outlook

  • 4.1. Global preimplantation genetic diagnosis revenue share, by type, 2015 & 2024
  • 4.2. PGD for chromosomal abnormalities
    • 4.2.1. PGD for chromosomal abnormalities market, 2013-2024(USD Million)
  • 4.3. PGD for HLA typing
    • 4.3.1. PGD for HLA typing market, 2013-2024(USD Million)
  • 4.4. PGD for X-linked diseases
    • 4.4.1. PGD for X-linked diseases market, 2013-2024(USD Million)
  • 4.5. PGD for gender selection
    • 4.5.1. PGD for gender selection market, 2013-2024(USD Million)
  • 4.6. PGD for Other genetic disorders
    • 4.6.1. PGD for other genetic disorders market, 2013-2024(USD Million)

Chapter 5: Preimplantation Genetic Diagnosis Application Outlook

  • 5.1. Global preimplantation genetic diagnosis revenue share, by application, 2015 & 2024
  • 5.2. Identification of HLA-compatible embryos for stem cell therapy
    • 5.2.1. HLA-compatible embryos for stem cell therapy market, 2013-2024(USD Million)
  • 5.3. Prognosis improvement in in-vitro fertilization patient
    • 5.3.1. IVF prognosis market, 2013-2024(USD Million)
  • 5.4. Late onset genetic disorders
    • 5.4.1. Late onset genetic disorders market, 2013-2024(USD Million)
  • 5.5. Inherited genetic disease
    • 5.5.1. Inherited genetic disease market, 2013-2024(USD Million)
  • 5.6. Others PGD applications
    • 5.6.1. Others PGD applications market, 2013-2024(USD Million)

Chapter 6: Preimplantation Genetic Diagnosis Regional Outlook

  • 6.1. Preimplantation genetic diagnosis revenue share, by region, 2015 & 2024
  • 6.2. North America
    • 6.2.1. North America preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.3. Europe
    • 6.3.1. Europe preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.3.2. Germany
      • 6.3.2.1. Germany preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.3.3. UK
      • 6.3.3.1. UK preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.4.3. China
      • 6.4.3.1. China preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Mexico preimplantation genetic diagnosis market, 2013-2024(USD Million)
  • 6.6. MEA
    • 6.6.1. MEA preimplantation genetic diagnosis market, 2013-2024(USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa preimplantation genetic diagnosis market, 2013-2024(USD Million)

Chapter 7: Competitive Landscape

  • 7.1. F. Hoffmann-La Roche AG
    • 7.1.1. Company Overview
    • 7.1.2. Financial Performance
    • 7.1.3. Product Benchmarking
    • 7.1.4. Strategic Initiatives
  • 7.2. Genea
    • 7.2.1. Company Overview
    • 7.2.2. Financial Performance
    • 7.2.3. Product Benchmarking
  • 7.3. Quest Diagnostics
    • 7.3.1. Company Overview
    • 7.3.2. Financial Performance
    • 7.3.3. Product Benchmarking
    • 7.3.4. Strategic Initiatives
  • 7.4. Illumina Inc.
    • 7.4.1. Company Overview
    • 7.4.2. Financial Performance
    • 7.4.3. Product Benchmarking
    • 7.4.4. Strategic Initiatives
  • 7.5. Natera
    • 7.5.1. Company Overview
    • 7.5.2. Financial Performance
    • 7.5.3. Product Benchmarking
    • 7.5.4. Strategic Initiatives
  • 7.6. Genesis Genetics LLC
    • 7.6.1. Company Overview
    • 7.6.2. Financial Performance
    • 7.6.3. Product Benchmarking
  • 7.7. Reprogenetics LLC
    • 7.7.1. Company Overview
    • 7.7.2. Financial Performance
    • 7.7.3. Product Benchmarking
    • 7.7.4. Strategic Initiatives
  • 7.8. Laboratory Corporation of America Holdings(LabCorp)
    • 7.8.1. Company Overview
    • 7.8.2. Financial Performance
    • 7.8.3. Product Benchmarking
    • 7.8.4. Strategic Initiatives
  • 7.9. Reproductive Genetics Institute Inc.
    • 7.9.1. Company Overview
    • 7.9.2. Product Benchmarking
    • 7.9.3. Strategic Initiatives
  • 7.10. California Pacific Medical Center
    • 7.10.1. Company Overview
    • 7.10.2. Financial Performance
    • 7.10.3. Product Benchmarking
    • 7.10.4. Strategic Initiatives

List of Tables

  • TABLE 1: Preimplantation Genetic Diagnosis Market - Industry Snapshot & Key Buying Criteria, 2013 - 2024
  • TABLE 2: Global preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 3: Global preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 4: Preimplantation genetic diagnosis market, by region, 2013 - 2024 (USD Million)
  • TABLE 5: Preimplantation genetic diagnosis- Key market driver analysis
  • TABLE 6: Global incidence rate of genetic disorders
  • TABLE 7: Preimplantation genetic diagnosis - Key market restraint analysis
  • TABLE 8: Risk of aneuploidy with rising maternal age
  • TABLE 9: North America preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 10: North America preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 11: U.S. preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 12: U.S. preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 13: Canada preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 14: Canada preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 15: Europe preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 16: Europe preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 17: Germany preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 18: Germany preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 19: UK preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 20: UK preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 21: Asia Pacific preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 22: Asia Pacific preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 23: Japan preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 24: Japan preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 25: China preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 26: China preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 27: Latin America preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 28: Latin America preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 29: Brazil preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 30: Brazil preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 31: Mexico preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 32: Mexico preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 33: Brazil preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 34: Brazil preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)
  • TABLE 35: South Africa preimplantation genetic diagnosis market, by type, 2013 - 2024 (USD Million)
  • TABLE 36: South Africa preimplantation genetic diagnosis market, by application, 2013 - 2024 (USD Million)

List of Figures

  • FIG. 1: Preimplantation genetic diagnosis market segmentation
  • FIG. 2: Global preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 3: Preimplantation genetic diagnosis market dynamics
  • FIG. 4: Abnormality in oocytes with increasing maternal age
  • FIG. 5: Key opportunities prioritized, 2015
  • FIG. 6: Preimplantation genetic diagnosis market Porter's analysis
  • FIG. 7: Preimplantation genetic diagnosis market PESTEL analysis
  • FIG. 8: Preimplantation genetic diagnosis revenue share, by type, 2015 & 2024
  • FIG. 9: PGD for chromosomal abnormalities market , 2013 - 2024 (USD Million)
  • FIG. 10: PGD for HLA typing market , 2013 - 2024 (USD Million)
  • FIG. 11: PGD for X-linked diseases market , 2013 - 2024 (USD Million)
  • FIG. 12: PGD for gender selection market , 2013 - 2024 (USD Million)
  • FIG. 13: PGD for other genetic disorders market , 2013 - 2024 (USD Million)
  • FIG. 14: Preimplantation genetic diagnosis revenue share, by application, 2015 & 2024
  • FIG. 15: HLA-compatible embryos for stem cell therapy market , 2013 - 2024 (USD Million)
  • FIG. 16: IVF prognosis market , 2013 - 2024 (USD Million)
  • FIG. 17: Late onset genetic disorders market , 2013 - 2024 (USD Million)
  • FIG. 18: Inherited genetic disease market , 2013 - 2024 (USD Million)
  • FIG. 19: Others PGD applications market , 2013 - 2024 (USD Million)
  • FIG. 20: Preimplantation genetic diagnosis market share, by region, 2015 & 2024
  • FIG. 21: North America preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 22: U.S. preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 23: Canada preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 24: Europe preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 25: Germany preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 26: UK preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 27: Asia Pacific preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 28: Japan preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 29: China preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 30: Latin America preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 31: Brazil preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 32: Mexico preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 33: MEA preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
  • FIG. 34: South Africa preimplantation genetic diagnosis market, 2013 - 2024 (USD Million)
Back to Top